Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$2.28 USD

2.28
7,179,830

+0.17 (8.06%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $2.26 -0.02 (-0.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Merck Ends Development of Two Experimental Cancer Drugs

by Zacks Equity Research

MRK's decision to discontinue the development of two cancer drugs follows a series of setbacks in multiple late-stage studies.

Zacks Equity Research

FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC

by Zacks Equity Research

The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.

Zacks Equity Research

Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Spero Therapeutics (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

CHMP Endorses Merck's Kidney Cancer Drug for Two Indications

by Zacks Equity Research

The CHMP's opinion is based on positive results from two late-stage studies on MRK's Welireg in two indications associated with renal cell carcinoma.

Zacks Equity Research

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

by Zacks Equity Research

Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.

Zacks Equity Research

ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline

by Zacks Equity Research

AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.

Zacks Equity Research

KRYS Stock Down on Initial Clinical Updates on KB407 & KB408

by Zacks Equity Research

Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat rare respiratory diseases.

Zacks Equity Research

SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy designation to Sanofi's tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis.

Zacks Equity Research

NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD

by Zacks Equity Research

Novo Nordisk's diabetes drug, Ozempic, receives positive CHMP opinion in the EU for expanded use in T2D and CKD patients.

Zacks Equity Research

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

by Zacks Equity Research

Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.